Repligen (NASDAQ:RGEN – Get Free Report) and vTv Therapeutics (NASDAQ:VTVT – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Repligen and vTv Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Repligen | 1 | 3 | 10 | 1 | 2.73 |
| vTv Therapeutics | 1 | 0 | 2 | 0 | 2.33 |
Repligen presently has a consensus target price of $169.62, indicating a potential upside of 12.47%. vTv Therapeutics has a consensus target price of $35.50, indicating a potential upside of 60.85%. Given vTv Therapeutics’ higher probable upside, analysts plainly believe vTv Therapeutics is more favorable than Repligen.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Repligen | $634.44 million | 13.37 | -$25.51 million | ($0.25) | -603.24 |
| vTv Therapeutics | $1.02 million | 69.02 | -$18.46 million | ($3.12) | -7.07 |
vTv Therapeutics has lower revenue, but higher earnings than Repligen. Repligen is trading at a lower price-to-earnings ratio than vTv Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Repligen has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, vTv Therapeutics has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.
Institutional and Insider Ownership
97.6% of Repligen shares are held by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are held by institutional investors. 1.2% of Repligen shares are held by insiders. Comparatively, 4.2% of vTv Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Repligen and vTv Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Repligen | -2.05% | 4.61% | 3.24% |
| vTv Therapeutics | N/A | -179.75% | -55.91% |
Summary
Repligen beats vTv Therapeutics on 9 of the 15 factors compared between the two stocks.
About Repligen
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
About vTv Therapeutics
vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
